These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26857900)

  • 1. Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.
    Hu M; Zhang Y; Xiang N; Zhong Y; Gong T; Zhang ZR; Fu Y
    Pharm Res; 2016 Jun; 33(6):1318-26. PubMed ID: 26857900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes.
    Zhang Y; Zhong Y; Hu M; Xiang N; Fu Y; Gong T; Zhang Z
    Drug Dev Ind Pharm; 2016; 42(7):1042-9. PubMed ID: 26558908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
    Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
    J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation.
    Chen C; Zheng H; Xu J; Shi X; Li F; Wang X
    Daru; 2017 Sep; 25(1):20. PubMed ID: 28870261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.
    Li XG; Li L; Zhou X; Chen Y; Ren YP; Zhou TY; Lu W
    Acta Pharmacol Sin; 2012 Nov; 33(11):1379-86. PubMed ID: 22659626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sol-gel transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus.
    Oh KS; Kim JY; Yoon BD; Lee M; Kim H; Kim M; Seo JH; Yuk SH
    Eur J Pharm Biopharm; 2014 Nov; 88(3):664-9. PubMed ID: 25152212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.
    Li H; Xu J; Fan X
    J Pharmacol Sci; 2015 Feb; 127(2):170-80. PubMed ID: 25727954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.
    Li X; Zhao Z; Li L; Zhou T; Lu W
    Drug Deliv; 2015 Jan; 22(1):86-93. PubMed ID: 24467493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide.
    Kim D; Jeon H; Ahn S; Choi WI; Kim S; Jon S
    J Control Release; 2017 Jun; 256():114-120. PubMed ID: 28457895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once weekly exenatide: efficacy, tolerability and place in therapy.
    Wysham C; Grimm M; Chen S
    Diabetes Obes Metab; 2013 Oct; 15(10):871-81. PubMed ID: 23425609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(l-lysine) block copolymer: potential implications on diabetic nephropathy.
    Tong F
    Int J Nanomedicine; 2017; 12():4663-4678. PubMed ID: 28721043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
    DeYoung MB; MacConell L; Sarin V; Trautmann M; Herbert P
    Diabetes Technol Ther; 2011 Nov; 13(11):1145-54. PubMed ID: 21751887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
    Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
    Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.
    Chen T; Kagan L; Mager DE
    J Pharm Sci; 2013 Oct; 102(10):3844-51. PubMed ID: 23897494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
    Tatarkiewicz K; Belanger P; Gu G; Parkes D; Roy D
    Diabetes Obes Metab; 2013 May; 15(5):417-26. PubMed ID: 23163898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
    Henry RR; Logan D; Alessi T; Baron MA
    Clin Ther; 2013 May; 35(5):634-645.e1. PubMed ID: 23578605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermo-reversible injectable gel based on enzymatically-chopped low molecular weight methylcellulose for exenatide and FGF 21 delivery to treat types 1 and 2 diabetes.
    Kim JK; Yoo C; Cha YH; Kim YH
    J Control Release; 2014 Nov; 194():316-22. PubMed ID: 25245775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
    Sakai T; Kusakabe T; Ebihara K; Aotani D; Yamamoto-Kataoka S; Zhao M; Gumbilai VM; Ebihara C; Aizawa-Abe M; Yamamoto Y; Noguchi M; Fujikura J; Hosoda K; Inagaki N; Nakao K
    Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E712-9. PubMed ID: 25159327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats.
    Kwak HH; Shim WS; Hwang S; Son MK; Kim YJ; Kim TH; Yoon ZH; Youn HJ; Lee GI; Kang SH; Shim CK
    Pharm Res; 2009 Nov; 26(11):2504-12. PubMed ID: 19756973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.